Darifenacin en es it fr

Darifenacin Brand names, Darifenacin Analogs

Darifenacin Brand Names Mixture

  • Cystosol W 3% Hexitols (Mannitol + Sorbitol)
  • Sorbitol Mannitol Irrigation (Mannitol + Sorbitol)

Darifenacin Chemical_Formula


Darifenacin RX_link


Darifenacin fda sheet

Darifenacin FDA

Darifenacin msds (material safety sheet)

Darifenacin Synthesis Reference

No information avaliable

Darifenacin Molecular Weight

426.55 g/mol

Darifenacin Melting Point

No information avaliable

Darifenacin H2O Solubility

No information avaliable

Darifenacin State


Darifenacin LogP


Darifenacin Dosage Forms

Extended-release tablets (containing 7.5 mg or 15 mg darifenacin as hydrobromide salt)

Darifenacin Indication

For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.

Darifenacin Pharmacology

Darifenacin is a competitive muscarinic receptor antagonist. In vitro studies using human recombinant muscarinic receptor subtypes show that darifenacin has greater affinity for the M3 receptor than for the other known muscarinic receptors (9 and 12-fold greater affinity for M3 compared to M1 and M5, respectively, and 59-fold greater affinity for M3 compared to both M2 and M4). Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of the urinary bladder smooth muscle and stimulation of salivary secretion. Adverse drug effects such as dry mouth, constipation and abnormal vision may be mediated through effects on M3 receptors in these organs.

Darifenacin Absorption

The mean oral bioavailability at steady state is estimated to be 15% and 19% for 7.5 mg and 15 mg tablets, respectively.

Darifenacin side effects and Toxicity

Overdosage can potentially result in severe central anticholinergic effects.

Darifenacin Patient Information

Darifenacin Organisms Affected

Humans and other mammals